4-(2-(indol-3-yl)vinyl)-1-methylpyridinium and Disease-Models--Animal

Colorectal cancer (CRC) is the third most prevalent type of cancer in the United States. The treatment options for cancer include surgery, chemotherapy, radiation, and/or targeted therapy, which show significant improvement in overall survival. Among the various available treatments, antagonizing VEGF/VEGFR-2 pathways have shown effectiveness in limiting colorectal cancer growth and improving clinical outcomes. In this regard, we hypothesized that F16, a novel VEGFR-2 inhibitor, would control colorectal cancer growth by blocking the VEGFR-2 singling pathway in both in vitro and in vivo conditions. Therefore, the current study was aimed to analyze the efficacy of F16 on the growth of Colo 320DM cells under in vitro and in vivo conditions.. Human RT. These results justify further evaluation of F16 as a potential new therapeutic agent for treating colorectal cancers.

Topics: Angiogenesis Inhibitors; Animals; Cell Line, Tumor; Cell Proliferation; Colorectal Neoplasms; Disease Models, Animal; Heterografts; Humans; Indoles; Mice; Protein Kinase Inhibitors; Pyridinium Compounds; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays